210

VISFATIN INCREASES INVASION IN HUMAN ADULT GRANULOSA TUMOR CELL LINE BY STIMULATION OF GLUCOSE METABOLISM REPROGRAMMING

J Gogola-Mruk*, K Krawczyk, W Marynowicz, A Ptak. Jagiellonian University, Institute of Zoology and Biomedical Research, Laboratory of Physiology and Toxicology of Reproduction, Kraków, Poland

10.1136/ijgc-2021-ESGO.357

Introduction/Background* Adult granulosa cell tumors (AGCT) accounting about 95% GCT (granulosa cell tumors) is characterized by the occurrence of an aggressive form and frequent appearance of recurrence and metastasis.¹ Furthermore, reports indicated that the level of visfatin, which is one of adipokine, is elevated in ascites fluid of ovarian cancer patients with diagnosed metastases.² Moreover, the role of visfatin in cancer metabolic reprogramming was demonstrated.³ Therefore, the aim of this research is to determine whether visfatin by reprogramming metabolism may be involved in invasion of AGCT

Methodology Human AGCT-derived cell line KGN (Riken Cell Bank) was cultured in three-dimensional culture. Spheroids were exposed to visfatin (100 ng/ml) for 24 h and invasion was measured using Culturex Spheroid Invasion Matrix (#3500-096-03; Trevigen). Glucose uptake was tested using a Glucose Uptake-Glo Assay (Promega) after treatment with visfatin (100 ng/ml) for 24h. Silencing of NAMPT (visfatin gene) was carried out using siRNA (SMART pool siRNA NAMPT; L-004581-00-0005) and basal glycolysis was measured using Seahorse Glycolytic Rate Assay (Agilent).

Result(s)* Firstly, we showed that visfatin increases KGN cells spheroids invasion. Furthermore, we observed stimulating glucose uptake in KGN cells after treatment with visfatin. Whereas the use of STF-31 (a blocker for the GLUT1 and an inhibitor of visfatin) abolished the stimulating effect of visfatin on the invasion, which indicates the important role of glucose metabolism in this process. Moreover, silencing of NAMPT decreased basal glycolysis in KGN cells spheroids.

Conclusion* These results stated that visfatin by reprogramming glucose metabolism plays an important role in increasing the ability of AGCT to invasion and because of that it can be a factor to progression of this cancer.

This study was funded by the National Science Centre (NCN) Poland (grant number 2019/33/N/NZ5/00471)

REFERENCES

1. Sonoyama A, Kanda M, Ojima Y, et al. *J Med Sci* 2015;**61**:E109-14.
2. Li Y, Li X, Liu KR, et al. *Eur J Cancer Prev* 2015;**24**:231-9.
3. Audrito V, Manago A, Gaudino F, et al. *Semin Cell Dev Biol* 2020;**98**:192-201.

217

THE IMPACT OF CHEMOTHERAPY RESPONSE SCORE AND LYMPHOCYTIC INFILTRATION IN PATIENTS WITH OVARIAN CANCER TREATED WITH NEOADJUVANT CHEMOTHERAPY

¹I Rodolakis*, ¹A Prodromidou, ²M Sotiropoulou, ³M Lontos, ¹D Haidopoulos, ³A Bamias, ¹D Loutradis, ¹N Thomakos, ¹A Rodolakis. ¹1st Department of Obstetrics and Gynecology, Medical School, National and Kapodistrian University of Athens, 'Alexandra' Hospital, Athens, Greece; ²Department of Pathology, General Hospital 'Alexandra', Athens, Greece; ³Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Alexandra Hospital, Athens, Greece

10.1136/ijgc-2021-ESGO.358

Introduction/Background* Neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS) represents an alternative approach to primary debulking for the management of advanced epithelial ovarian cancer (EOC) with comparable survival outcomes. Histopathologic examination of the IDS specimens and the evaluation of Chemotherapy Response Score (CRS) have been proposed as significant markers of response to NACT. The aim of the present study was to evaluate the prognostic significance of CRS in OC patients treated with NACT.

Methodology A single institution retrospective analysis of patients with OC stage $\geq$ III who were selected to receive NACT from 2011 to 2018 was performed. Omental and ovarian samples were assessed for the evaluation of CRS according to International Collaboration on Cancer Reporting (ICCR) recommendation. Lymphocytic infiltration, presence of necrosis and mitotic index were also assessed.

Result(s)* The final analysis included a total of 60 patients with median age of 65 years at diagnosis. Omentum and ovarian samples of the included patients revealed a CRS 3 in 20 and 10 patients, respectively. Patients with CRS3 at omentum had significantly prolonged median progression free survival (PFS) compared to CRS1 and CRS2 (19 vs 10 vs 15 months, respectively, $p=0.002$), while no difference was observed in the respective OS among the groups (42 vs 28 vs 32.3 months, respectively). Lymphocytic infiltration in pre-treatment biopsies was related to improved PFS and OS (log-rank $p=0.01$ and $p=0.015$, respectively). No effect on either PFS or OS was observed in patients who received bevacizumab post-IDS, while in patients with lymphocytic infiltration bevacizumab negatively affected PFS.

Conclusion* CRS seems to play a key role in the prediction of the postoperative course of EOC patients who received NACT and IDS. However, further studies are warranted to decipher the exact role of CRS and lymphocytic infiltration so as to personalize the treatment of EOC patients.

219

SKIN CAPILLARY DENSITY AS A NOVEL BIOMARKER OF CYTOTOXIC AND BEVACIZUMAB TREATMENT IN OVARIAN CANCER: A PROSPECTIVE CLINICAL TRIAL

¹G Cass*, ²R Lewes, ³J Pawade, ¹C Newton. ¹University Hospitals Bristol NHS Foundation Trust Headquarters, UK; ²University of Bristol, UK; ³North Bristol NHS Trust, UK

10.1136/ijgc-2021-ESGO.359

Introduction/Background* The role of angiogenesis in ovarian cancer progression is well established. Bevacizumab has been demonstrated to have a survival advantage for a subgroup of women with stage 4 disease and those who have suboptimal debulking surgery. The search for a biomarker of Bevacizumab efficacy is elusive. Skin capillary density (SCD) is a dynamic marker that may provide a surrogate indicator of angiogenic activity and alter in response to treatment in cancer patients.

Methodology A cohort of 50 women with stage 3 and 4 high grade serous cancer were enrolled over 2 years at University Hospitals Bristol, UK. Written informed consent was obtained from each participant. SCD was measured at baseline and at specified time points during treatment. Serum angiogenic markers (VEGF and Ang 1) and tissue micro vessel density and proliferation (ki67) were also measured and correlated with SCD. Longitudinal and survival analysis was conducted to ascertain changes in SCD during treatment and association

with cancer outcomes including surgical resection, overall survival (OS) and progression free survival (PFS). Correlations were investigated between SCD and tumour vascularity.

Result(s)* Capillary rarefaction occurred in all patients during cytotoxic treatment ($p < 0.001$). This correlated with a decline in VEGF and Ang 1 ($p = 0.02$, $p < 0.001$). Rarefaction was greater in the subgroup of patients who received Bevacizumab and was strongly correlated with a rise in blood pressure. Baseline SCD was strongly associated with the outcome of debulking surgery ($p = 0.001$). Patients who had a smaller reduction in skin capillary density during treatment had a worse PFS ($p = 0.01$). Vessel density in the tumour reduced after treatment and was more significant in patients who received Bevacizumab. There was no correlation between SCD and tumour vascularity.

Conclusion* Skin capillary rarefaction occurs during both cytotoxic and anti angiogenic treatment in women with ovarian cancer. SCD could be useful as a biomarker of response to treatment and cancer outcomes and act as a surrogate marker of angiogenesis in cancer. It is a reproducible, cheap and non-invasive investigation that is acceptable to patients and shows promise in helping to guide treatment and prognostic information in the era of personalised medicine.

221

ABSTRACT WITHDRAWN

225

AVELUMAB ALONE IN PLATINUM-RESISTANT/REFRACTORY OVARIAN CANCER: SELECTED BIOMARKER ANALYSES FROM THE JAVELIN OVARIAN 200 TRIAL

¹E Pujade-Lauraine*, ^{2,3}J Ledermann, ⁴A Oza, ^{2,3}R Kristeleit, ^{5,6}J Ray-Coquard, ⁷G Richardson, ⁸C Sessa, ⁹K Yonemori, ^{10,11}S Banerjee, ^{12,13}A Leary, ¹⁴X Mu, ¹⁴Y Liu, ¹⁴K Ching, ¹⁴S Deng, ¹⁵J Perkins Smith, ¹⁴A Donahue, ¹⁶K Fujiwara, ^{17,18}B Monk. ¹ARCAGY-GINECO, Paris, France; ²UCL Cancer Institute, London, UK; ³UCL Hospitals, London, UK; ⁴Princess Margaret Cancer Centre, Toronto, Canada; ⁵Centre Léon Bérard, Service de Cancérologie Médicale, Université Claude Bernard Lyon 1, Lyon, France; ⁶GINECO, Lyon, France; ⁷Cabrini Hospital, Department of Medical Oncology, Malvern, Australia; ⁸Oncology Institute of Southern Switzerland (IOSI), Ospedale San Giovanni, Bellinzona, Switzerland; ⁹National Cancer Center Hospital, Chuo-ku, Department of Breast and Medical Oncology, Tokyo, Japan; ¹⁰The Royal Marsden NHS Foundation Trust, London, UK; ¹¹The Institute of Cancer Research, London, UK; ¹²Gustave Roussy Cancer Campus, Villejuif, France; ¹³GINECO, Villejuif, France; ¹⁴Pfizer, San Diego, USA; ¹⁵Pfizer Inc, New York, USA; ¹⁶Saitama Medical University International Medical Center, Saitama, Japan; ¹⁷Arizona Oncology (US Oncology Network), Phoenix, USA; ¹⁸University of Arizona College of Medicine, Creighton University School of Medicine, Phoenix, USA

10.1136/ijgc-2021-ESGO.360

Introduction/Background* In the randomized phase 3 JAVELIN Ovarian 200 trial (N=566), avelumab alone or combined with pegylated liposomal doxorubicin (PLD) did not significantly prolong progression-free survival (PFS; blinded independent central review) or overall survival (OS) vs PLD alone in patients with platinum-resistant/refractory ovarian cancer (PRROC). Here, we report exploratory biomarker analyses associated with outcomes in the avelumab alone arm.

Methodology Biomarkers analyzed in tumour tissue or blood were somatic and germline mutations by whole-exome sequencing and whole-transcriptomic profiling by RNAseq. Associations were assessed using the Cox proportional hazards

model. For continuous biomarkers, hazard ratios (HRs) and 95% CIs were reported using a median cutoff.

Result(s)* Within the avelumab alone arm, higher expression of CD8+ T-cell signature correlated with longer PFS (HR, 0.61 [95% CI 0.43-0.87]), and higher tumour mutational burden (> 0.6 mut/Mb) and presence of the high-affinity FCGR2A allele correlated with longer OS (HR [95% CI], 0.63 [0.42-0.96] and 0.53 [0.34-0.83], respectively), while presence of APOBEC and homologous recombination deficiency (HRD) mutational signatures were associated with shorter OS (HR [95% CI], 2.17 [1.22-3.89] and 1.68 [1.07-2.62], respectively). In patients with PFS of < 6 months, a lower score for several signatures, including P53 and angiogenesis, predicted better outcomes within the avelumab alone arm (HR [95% CI], 0.37 [0.23-0.60] and 0.52 [0.33-0.82], respectively). BRCA1/2 mutations (germline and/or somatic) were not associated with improved outcomes. Within the avelumab alone arm, higher expression of TGF- β signaling, estrogen receptor early expression signature, and epithelial-to-mesenchymal transition gene signatures correlated with shorter OS (HR [95% CI], 1.64 [1.10-2.47], 1.63 [1.09-2.45], and 1.57 [1.05-2.35], respectively). Higher expression of signatures for mesenchymal cells, cancer-associated fibroblasts, and fat cells were marginally associated with shorter OS (HR [95% CI], 1.47 [0.97-2.23], 1.45 [0.95-2.21], and 1.50 [0.99-2.27], respectively). Multivariable analyses are ongoing.

Conclusion* Although JAVELIN Ovarian 200 did not meet its primary endpoints, these analyses indicate potential subgroups of patients who could have improved outcomes with immunotherapy alone and provide insights into the biology of PRROC that may inform future trials.

229

AVELUMAB COMBINED WITH PEGYLATED LIPOSOMAL DOXORUBICIN IN PLATINUM-RESISTANT/REFRACTORY OVARIAN CANCER: BIOMARKER ANALYSES FROM JAVELIN OVARIAN 200

¹E Pujade-Lauraine*, ^{2,3}J Ledermann, ⁴A Oza, ^{2,3}R Kristeleit, ^{5,6}J Ray-Coquard, ⁷G Richardson, ⁸C Sessa, ⁹K Yonemori, ^{10,11}S Banerjee, ^{12,13}A Leary, ¹⁴X Mu, ¹⁴Y Liu, ¹⁴K Ching, ¹⁴S Deng, ¹⁵J Perkins Smith, ¹⁴A Donahue, ¹⁶K Fujiwara, ^{17,18}B Monk. ¹ARCAGY-GINECO, Paris, France; ²UCL Cancer Institute, London, UK; ³UCL Hospitals, London, UK; ⁴Princess Margaret Cancer Centre, Toronto, Canada; ⁵Centre Léon Bérard, Service de Cancérologie Médicale, Université Claude Bernard Lyon 1, Lyon, France; ⁶GINECO, Lyon, France; ⁷Cabrini Hospital, Department of Medical Oncology, Bellinzona, Switzerland; ⁸Oncology Institute of Southern Switzerland (IOSI), Ospedale San Giovanni, Bellinzona, Switzerland; ⁹National Cancer Center Hospital, Chuo-ku, Department of Breast and Medical Oncology, Tokyo, Japan; ¹⁰The Royal Marsden NHS Foundation Trust, London, UK; ¹¹The Institute of Cancer Research, London, UK; ¹²Gustave Roussy Cancer Campus, Villejuif, France; ¹³GINECO, Villejuif, France; ¹⁴Pfizer, San Diego, USA; ¹⁵Pfizer Inc, New York, USA; ¹⁶Saitama Medical University International Medical Center, Hidaka, Saitama, Japan; ¹⁷Arizona Oncology (US Oncology Network), Phoenix, USA; ¹⁸University of Arizona College of Medicine, Creighton University School of Medicine, Phoenix, USA

10.1136/ijgc-2021-ESGO.361

Introduction/Background* In the randomized phase 3 JAVELIN Ovarian 200 trial (N=566), avelumab alone or combined with pegylated liposomal doxorubicin (PLD) did not significantly prolong progression-free survival (PFS; blinded independent central review) or overall survival (OS) vs PLD alone in patients with platinum-resistant/refractory ovarian cancer (PRROC). Here, we report exploratory biomarker analyses associated with outcomes in the avelumab alone arm.